Pharmacokinetics and safety of a phenytoin prodrug given i.v. or i.m. in patients.
ACC-9653, a prodrug of phenytoin synthesized to be water soluble, is converted to phenytoin by phosphatases. In this study, 43 patients received ACC-9653 IV or IM. Side effects were transient and minor. The conversion half-lives of ACC-9653 after intravenous and intramuscular administration averaged 8.4 and 32.7 minutes, respectively. Peak phenytoin concentrations occurred 42 minutes after IV and 151 minutes after IM administration.
Leppik
I E
IE
Department of Neurology, University of Minnesota, Minneapolis 55414.
Boucher
B A
BA
Wilder
B J
BJ
Murthy
V S
VS
Watridge
C
C
Graves
N M
NM
Rangel
R J
RJ
Rask
C A
CA
Turlapaty
P
P
D000328:Adult; D000368:Aged; D004562:Electrocardiography; D004827:Epilepsy / Q000188:drug therapy*; D005260:Female; D006207:Half-Life; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D007273:Injections, Intramuscular; D008297:Male; D008875:Middle Aged; D010672:Phenytoin / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D011355:Prodrugs / Q000008:administration & dosage / Q000493:pharmacokinetics*
D011355:Prodrugs; D010672:Phenytoin; C043114:fosphenytoin